Roivant Sciences Quarterly Cash Flow Statement
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Roivant Sciences free cash flow
In the quarter ended Jun 30, 2026, Roivant Sciences generated -$270.5 million of operating cash flow and spent $419,000 on capital expenditures. That left free cash flow of -$270.9 million, a free-cash-flow margin of -18788.0% of revenue. Roivant Sciences returned $206.7 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
Roivant Sciences cash flow statement (quarterly)
| Quarter (USD) | Q1 20262026-06-30 | Q4 20252026-03-31 | Q3 20252025-12-31 | Q2 20252025-09-30 | Q1 20252025-06-30 | Q4 20242025-03-31 | Q3 20242024-12-31 | Q2 20242024-09-30 | Q1 20242024-06-30 | Q4 20232024-03-31 | Q3 20232023-12-31 | Q2 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -290.61M | 355.74M | -313.70M | -166.04M | -273.91M | -252.38M | 118.08M | -279.92M | 57.49M | -182.50M | 5.07B | -331.12M |
| Net Income growth (YoY) | — | — | -365.68% | — | -576.45% | — | -97.67% | — | — | — | — | — |
| Depreciation & Amortization | 600.00K | 638.00K | 691.00K | 921.00K | 1.10M | 1.43M | 2.92M | 4.84M | 4.88M | 5.22M | 5.38M | 5.59M |
| Stock-Based Compensation | 83.34M | 77.17M | 105.00M | 81.82M | 82.18M | 83.49M | 83.68M | 71.67M | 50.19M | 46.72M | 54.33M | 49.32M |
| Change in Working Capital | 15.04M | 79.38M | 4.59M | 15.52M | -5.88M | 9.27M | -2.98M | 28.32M | -62.85M | 76.82M | -11.74M | 35.77M |
| Operating Cash Flow | -270.50M | -163.82M | -196.48M | -185.66M | -204.38M | -172.56M | -207.25M | -266.81M | -192.83M | -108.46M | -210.45M | -196.43M |
| Capital Expenditures | -419.00K | -1.26M | 4.93M | -7.85M | -4.04M | -811.00K | -1.83M | -996.00K | -965.00K | -349.00K | -355.00K | -275.00K |
| Investing Cash Flow | 281.26M | 173.49M | 109.47M | 120.42M | -1.09B | 1.07B | 454.07M | -3.29B | -965.00K | 6.93M | 5.23B | -36.45M |
| Share Repurchases | -206.73M | — | 0 | 0 | -208.29M | -295.44M | -243.35M | -106.05M | -648.38M | 0 | 0 | 0 |
| Financing Cash Flow | -181.51M | -68.78M | 328.19M | 62.59M | -187.77M | -177.15M | -272.95M | -109.07M | -660.62M | -32.62M | 236.64M | 207.87M |
| Net Change in Cash | -170.44M | -57.79M | 241.61M | -1.45M | -1.48B | 723.99M | -27.20M | -3.66B | -857.15M | -135.01M | 5.26B | -26.46M |
| Free Cash Flow | -270.92M | -165.08M | -191.55M | -193.51M | -208.42M | -173.38M | -209.08M | -267.80M | -193.79M | -108.81M | -210.81M | -196.70M |
This table shows 12 quarterly periods of Roivant Sciences's cash flow statement, from Q1 2026 back to Q2 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ROIV's reporting calendar. What is a cash flow statement?